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Aims: In epithelial ovarian cancer (EOC), activation of endothelin-1 (ET-1)/endothelin A receptor (ETAR) signal-
ling is linked to many tumor promoting effects, such as proliferation, angiogenesis, invasion and metastasis.
These effects are dependent by the activation of critical signalling pathways, such as MAPK, Akt, and β-catenin,
through specific cytosolic and nuclear scaffolding functions of β-arrestin 1 (β-arr1). Here, we have assessed
the potential role of ET-1/ETAR in promoting NF-κB signalling in EOC cells through β-arr-1 recruitment.
Main methods:We used cultured HEY EOC cells cultured in the presence or absence of ET-1 and the ETAR antag-
onist BQ123. The phosphorylation of p65 and Iκ-Bαwas evaluated by immunoblotting analysis. The interaction
between p65 andβ-arr1was evaluated by immunoprecipitation experiments in nuclear extracts. NF-κB promot-
er activity was evaluated by transfection with NF-κB-driven luciferase reporter construct. Assessment of the
function of β-arr1 was achieved by β-arr1 silencing with shRNA and expression of β-arr1-FLAG expression
vector.
Key findings: In EOC cells, ET-1 promotes the phosphorylation of p65 subunit and the cytoplasmic inhibitor IκB
that in turn led to increased NF-κB transcriptional activity. These effects were inhibited by the use of BQ123, as
well as by β-arr-1 silencing, suggesting that ET-1 through ETAR promotes the recruitment of β-arr1 to regulate
NF-κB signalling.Moreover, the nuclear physical interaction between p65 andβ-arr1 indicates a nuclear function
of β-arr-1 in ETAR-driven NF-κB transcriptional activity.
Significance: Altogether these findings reveal a previously unrecognized pathway that depends on β-arr1 to
sustain NF-κB signalling in response to ETAR activation in ovarian cancer.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
It has been shown that endothelin-1 (ET-1)/endothelin A receptor
(ETAR) system plays an important role in tumorigenesis and progres-
sion in many types of human cancers, including epithelial ovarian can-
cer (EOC), representing a key driver in promoting cell proliferation,
escape from apoptosis, angiogenesis, invasion, and metastasis (Rosanò
et al., 2013a). Moreover, ET receptors are the first family of G protein-
coupled receptors (GPCRs) that have the prospect of being targeted
for cancer therapy (Bagnato et al., 2011). Stimulation of EOC cells withathology Regina Elena National
el.: +39 0652662565; fax: +39
ifo.it (L. Rosanò).
. This is an open access article underET-1 initiates a series of signalling cascades and leads to activation of
several transcription factors and intracellular pathways, including
MAPK, Akt, and β-catenin (Rosanò et al., 2013a). Although ET-1 acti-
vates these signalling cascades by binding to its GPCRs, ETAR and ETBR,
on the cell surface, and by association with the trimeric G protein
complex, emerging evidences indicate that ET-1 receptors also associate
withβ-arrestin (β-arr) upon stimulation of ET-1 (Shenoy and Lefkowitz,
2011; Rosanò et al., 2009, 2013b; Spinella et al., 2013). β-arr-1 and
β-arr-2 regulate the function of most GPCRs and are expressed ubiq-
uitously (Shukla et al., 2011). It has been reported that β-arrs are in-
volved in various signalling pathways, leading to the activation of
MAPK, PI3K and Akt (Shenoy and Lefkowitz, 2011; Shukla et al.,
2011). In particular, it has been demonstrated that β-arr-1 and -2
are scaffold proteins that bind to ETAR and ETBR and that serve as
molecular ‘hubs’ to organize complex signalling networks, leading
to activation of β-catenin signalling and to the transactivation of re-
ceptor tyrosine kinases such as epidermal growth factor receptor
(EGFR) and vascular endothelial growth factor receptor 3 (VEGFR3),the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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2013; Cianfrocca et al., 2010).
In different cancer cells, the binding of ligands, such as ET-1, with
several GPCR can induce the activation of nuclear factor κB (NF-κB), a
family of transcription factors that exist as various homo- and heterodi-
mers (Morinelli et al., 2013; Gupta et al., 2012; Delekta et al., 2010 Dec
31; Sun and Lin, 2008; Kizaki et al., 2009; Yang et al., 2009). As for many
activators of NF-κB, this occurs through the so-called canonical path-
way, whereby activation depends upon stimulation of the IκB kinase
(IKK) complex (DiDonato et al., 2012). In unstimulated cells, NF-κB is
associated with a family of inhibitor protein, IκB, which masks the
nuclear localization signal of NF-κB, thereby sequesteringNF-κB (partic-
ularly in the form of RelA/p65) in the cytoplasm. Various stimulation
signals activate the IKK complex,which phosphorylates IκBα and rapid-
ly triggers a ubiquitination-mediated degradation of IκBα. Furthermore,
phosphorylation of the p65 subunit in one of two of its transactivation
domains has been shown to be essential for NF-κB transcriptional
activation (Naumann and Scheidereit, 1994). The degradation of IκBα
releases NF-κB, which translocates into the nucleus and binds to the
cognate sequences in the promoter of its target genes (Moreno et al.,
2010), leading to the modulation of various biological responses in
cancer, including cell survival and proliferation, immunity, and inflam-
mation (Elinav et al., 2013). ET-1 induces NF-κB p65 via ETAR in various
tumor cell lines (von Brandenstein et al., 2008). A pioneer study pro-
vides evidence that in prostate cancer cells ET-1 activates NF-κB
through autocrine loop and that an ETAR antagonist abrogates NF-κB
activation favoring proapoptotic environment, leading to greater killing
when combined with chemotherapeutic agents (Banerjee et al., 2007;
Mangelus et al., 2001). Moreover, it has been demonstrated that activa-
tion of NF-κB might be involved in the induction of migration activity
caused by ET-1 stimulation in cancer cells (Wu et al., 2012). However,
the molecular mechanism of ET-1-induced NF-κB activation is not
fully defined. In this work, we have investigated the role of β-arr-1 in
NF-κB activation induced by ET-1. We found that β-arr-1 functions as
a positive regulator for ET-1-induced NF-κB activation in ovarian cancer
cells. Moreover, we demonstrated that the specific inhibition of ETAR
by the receptor antagonist BQ123, by blocking the interaction of ETAR
with β-arr-1, controls the transcriptional activation of NF-κB.
Materials and methods
Cell lines and reagents
The established human ovarian serous adenocarcinoma cell line,
HEY, obtained by Prof. Giovanni Scambia (Catholic University School
of Medicine, Rome, Italy), and cultured as previously described
(Rosanò et al., 2009), was passaged in our laboratory for fewer than
3 months after resuscitation. All cells were tested routinely for cell
proliferation (3H-thymidine incorporation) as well as mycoplasma
contamination, and they showed similar growth rate and negative
mycoplasma during the experiments. Cells were serum starved by incu-
bation 24 h in serum-free medium prior to each experiment. ET-1
(100 nM) and BQ123, Cyclo(-D-Trp-D-Asp-Pro-D-Val-Leu) (1 μM)
were purchased from Bachem (Switzerland). NFκB inhibitory ligand
(36 μM) was purchased from Upstate (Millipore).
Quantitative real-time-PCR
Total RNA was isolated using the TRIzol (Invitrogen) according to
the manufacturer's protocol. 5 μg of RNA was reversed transcribed
using the SuperScript® VILO™ cDNA synthesis kit (Invitrogen). Quanti-
tative real-time-PCRwas performed by using the LightCycler rapid ther-
mal cycler system (Roche Diagnostics) according to the manufacturer's
instructions. The number of each gene-amplified product was normal-
ized to the number of cyclophilin-A amplified product. Each qPCR
analysis was done twice separately.The primer sets used were as follows:
ETAR F: GTCTGCTGTGGGCAATAGTTG
ETAR R: GCTTCCTGGTTACCACTCATCAA
ETBR F: TCAACACGGTGGTGTCCTGC
ETBR R: ACTGAATAGCCACCAATCTT
Bcl-2 F: CTGCACCTGACGCCCTTCACC
Bcl-2 R: CACATGACCCCACCGAACTCAAAGA
MMP-2 F: GGATGATGCCTTTGCTCG
MMP-2 R: ATAGGATGTGCCCTGGAA
Cyclophilin F: TTCATCTGCACTGCCAAGAC
Cyclophilin R: TCGAGTTGTCCACAGTCAGC
RNA silencing
The lentiviral-based short hairpin RNAs (shRNA) plasmids
(pLKO.1 plasmids) used to knockdown β-arr1 were purchased from
Sigma. Five plasmid-clones were tested for their knockdown effi-
ciency (TRCN0000230149; TRCN0000230147; TRCN0000005160;
TRCN0000005161; TRCN0000230150). Non-target shRNA control
vector (SRC) was used as negative control. Transient transfection
was performed by adding 2 μl/well of shRNA plasmid along with
5 μl/well LipofectAMINE 2000 (Invitrogen) in 6-well plates for 48 h.
β-Arr1 plasmid and transfection constructs
For exogenous expression of β-arr1, we used pcDNA3-β-arr1-FLAG
(wild type) plasmid construct, a “wobble” mutant construct encoding
rat β-arr1 sequences resistant to siRNA targeting kindly provided
by Dr. Robert Lefkowitz (Howard Hughes Medical Institute, Duke
University). For transient expression of β-arr1-FLAG, 2 μg of each
construct was transfected in cells using LipofectAMINE 2000 reagent
(Invitrogen) following the manufacturer's instructions. Cells transfected
with the empty vector pCDNA3were used as control (Mock transfected).
Immunoblotting and immunoprecipitation
Cellswere lysed in lysis buffer [250mMNaCl, 50mMHEPES (pH 7.4),
1 mM ethylenediaminetetraacetic acid (EDTA), 1% Nonidet P-40, prote-
ase inhibitors]. NE-PER nuclear and cytoplasmic extraction reagents
(Pierce Biotechnology) were used to separate cytoplasmic and nuclear
fractions. Protein content of the extracts was determined using the Bio-
Rad protein assay kit. Cell lysates were resolved by SDS-PAGE and trans-
ferred to 0.45 μm nitrocellulose membranes (Bio-Rad Laboratories), and
the interacting proteins were detected by immunoblotting (IB) with the
following antibodies (Abs): NF-κB p65, phospho-NF-κB p65 (Ser536),
IκB-α, phospho-IκB-α (Ser32/36) (Cell Signalling) and α-tubulin (Santa
Cruz Biotechnology). For the IP assays, the nuclear extracts were treated
with 15 μ/ml of DNase I (Invitrogen) and precleared cell lysates were
incubated with β-arr-1 Abs (Santa Cruz Biotechnology) and protein
A-agarose beads (Amersham Pharmacia Biotech) at 4 °C overnight.
The IP and input (3% of the total nuclear extracts) samples were boiled
for 5 min in SDS loading buffer, loaded onto 10% SDS/PAGE, and trans-
ferred to nitrocellulose membrane and IB with different Abs as before.
To obtain clean and specific IB signals of β-arr1 which run very close
to heavy chain of IgG, we used HRP-conjugated protein A (Pierce) in-
stead of HRP-conjugated secondary Ab. Blots were developed with the
enhanced chemiluminescence detection system (ECL; GE Healthcare
Life Sciences).
Luciferase reporter gene assay
To measure the NF-κB promoter activity, cells were transiently
cotransfected with NFκB-luc vector that contains multiple copies of
the NF-κB consensus sequence fused to a TATA-like promoter (PTAL)
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galactosidase vector (Promega) using LipofectAMINE 2000 reagent
(Invitrogen). Reporter activity was measured using the Luciferase
assay system (Promega) and normalized to β-galactosidase activity.
The mean of three independent experiments performed in sextuplicate
was reported.
Statistical analysis
Statistical analysis was performed using Student's t test and Fisher's
exact test as appropriate. All statistical tests were carried out using the
SPSS software (SPSS 11, SPSS Inc. Chicago, IL). A two-sided probability
value of b0.05 was considered statistically significant.
Results
ET-1 activates NF-κB pathway in human ovarian cancer cells through ETAR
To perform our study, we used the human ovarian cancer cell line
HEY, which expresses ETAR at higher levels compared to ETBR, as
shown by real-time-PCR analysis (Fig. 1A). In order to evaluate the abil-
ity of ET-1 to activate the NF-κB pathway, we transiently transfected
HEY cells with a luciferase reporter plasmid under the control of a
synthetic promoter that contains direct repeats of the transcription rec-
ognition sequences for NF-κB (pNF-κB-Luc) or in parallel to a negative
control (pTAL-Luc). As shown in Fig. 1B, ET-1 treatment (100 nM), a
dose capable to induce maximum agonist response, for 24 h was able
to increase NF-κB-driven luciferase expression (1.5-fold). Then, we
found that the addition of 1 μM BQ123, a peptide ETAR antagonist,
inhibited the ability of ET-1 to induce NF-κB activity (Fig. 1B, indicating
that ETAR mediates the ET-1 response of the NF-κB pathway in these
cells. NF-κB is a complex of proteins, including p50 and p65 subunits.
Given that the phosphorylation of p65 is required for NF-κB transcription-
al activity (Moreno et al., 2010),we used a specific antibody against phos-
phorylated p65 (Ser536).We found that treatment of HEY cells with ET-1
resulted in the p65 phosphorylation, starting from 5 min until 60 min
(Fig. 1C) and, according to the above results, BQ123 inhibited the abilityFig. 1. A. qPCR for ETAR and ETBR expression in HEY cells. Values aremean± SD of 3measurem
(1 μM), transiently cotransfected with NFκB-luciferase (WT)reporter construct or with negativ
mean of 6measurements ± SD. *, p b 0.002 vs control (C); **, p b 0.05 vs ET-1. C. Immunoblotti
cells treated with ET-1 (100 nM) at different times. D. Protein expression of HEY cells, treated fo
uated by IB using the following Abs: NF-κB p65, phospho-NF-κB p65 (Ser536), IκB-α, phosphoof ET-1 to induce the p65 Ser536 phosphorylation (Fig. 1D). A key event
in the activation of theNF-κB pathway is the phosphorylation of the cyto-
plasmic inhibitor IκB that drives ubiquitination and degradation, lead-
ing to the release of p50/p65 heterodimer, nuclear translocation, and
transcriptional activity (Yaron et al., 1997; Mercurio et al., 1997). Stim-
ulation of cells with ET-1 induced IκB-►αphosphorylation (Ser 32/36)
and the addition of BQ123 prevented this phosphorylation (Fig. 1D),
confirming that ET-1 through ETAR causes rapid activation of the canon-
ical NF-κB pathway in ovarian cancer cells.Specific requirement of β-arrestin-1 for ET-1-induced NF-κB activation
Earlier studies indicate that β-arrs associate with GPCRs, which
mediates receptor endocytosis, and also function as adaptors to form
“signalosomes” facilitating GPCR signalling pathways (Shenoy and
Lefkowitz, 2011). More recently, it has been shown that β-arr can
bind to IκBα, leading to suppression of NF-κB activation induced by
TNFα, IL-1β, and UV light (Wang et al., 2006; Luan et al., 2005;
Witherow et al., 2004; Gao et al., 2004). To address whether ET-1
might recruit β-arr-1 to induce NF-κB activation, we stimulated cells
silenced for β-arr-1 or overexpressing β-arr-1 with ET-1 and then
examined NF-κB luciferase activity. Interestingly, we found that ET-1
stimulation failed to induce NF-κB activation in β-arr1 silenced cells,
whereas the overexpression of β-arr1 rescued this effect (Fig. 2A and
B), suggesting that β-arr-1 might function as a positive regulator of
ET-1-dependent NF-κB signalling. To confirm the results, we evaluated
by real-time-PCR analysis the expression of genes known as NF-κB
target genes, such as bcl-2 and matrix metalloprotease-2 (MMP-2) in
cells silenced for β-arr-1 or treated with a specific NF-κB inhibitor,
which inhibits translocation of NF-kappa B to the nucleus. According
to the above results, the silencing of β-arr1 led to reduced expression
of bcl-2 and MMP-2 in the same extent of the NF-κB inhibitor
(Fig. 2B). Next, we sought to determine whether β-arr1 links also com-
plexes with p65. Cytosolic and nuclear fractions were made from
unstimulated and ET-1-stimulated HEY cells, incubated with an anti-
p65 antibody for IP, and analyzed by Western blot for the co-IP of the
β-arr1. Following the stimulation there was an increase in theents. B. NF-κB reporter activity in HEY cells treated with ET-1 (100 nM) and/or with BQ123
e control(NC) pTAL-Luc construct, together with pCMV-β-galactosidase vector. Values are
ng (IB) for phospho-NF-κB p65 (Ser536) and NF-κB p65 expression in total extracts of HEY
r 5 minwith ET-1 (100 nM) in the presence or in the absence of BQ123 (1 μM), was eval-
-IκB-α (Ser32/36).
Fig. 2.A.NF-κB reporter activity inHEY cells treatedwith ET-1 (100 nM) and transfectedwith non-target shRNA control vector (SCR) or silenced forβ-arr1 (sh-β-arr1) and/or rescuedwith
β-arr1 or with the empty vector pCDNA3 (Mock). Values are mean of 6 measurements ± SD. *, p b 0.002 vs control of SCR-Mock transfected cells; **p b 0.05 vs ET-1-treated SCR-Mock
transfected cells; ***, p b 0.001 vs sh-βarr1-Mock transfected cells. B. qPCR for bcl-2 andMMP-2 expression inHEY cells transfectedwith non-target shRNA control vector (SCR) or silenced
for β-arr1 (sh-β-arr1) or treated with a specific NF-κB inhibitor. Values are mean ± SD of 3 measurements. *p b 0.02 vs SCR-transfected cells C. Lysates of HEY cells treated as in A were
evaluated by IB using anti-β-arr-1. Anti-α-tubulinwas used as loading control. D. Cytosolic and nuclear extracts of HEY cells treated for 24 hwith ET-1 (100 nM)were IPwith anti-β-arr1
and IB with anti-NF-κB p65 and anti-β-arr1 Abs.
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along with increased β-arr1 nuclear accumulation.
Discussion
Among cancer-specific targets in human cancers, several studies
have reported that increased ETAR expression in human tumor tissues
is related to cancer progression (Rosanò et al., 2013a). The binding of
ET1 to its cognate receptor triggers the activation of a diverse network
of signalling pathways, including MAPK, NF-κB, PI3K-AKT, β-catenin,
and hypoxia inducible factor (HIF)1α, to drive cell growth, angiogene-
sis, invasion and metastasis. Although many of these signalling path-
ways are well studied in human cancer cells, the role of ET-1 toFig. 3. Proposedmechanismbywhich β-arr1 regulates ET-1-inducedNF-κB activity in epithelia
induces the concomitant phosphorylation of p65 (Ser536) and IκB-α (Ser 32/36), key events in t
and together translocates in the nucleus, promoting NF-κB p65 transcriptional activity.activate NF-κB signalling and molecular mechanism underlying this ac-
tivation in ovarian cancer remains to be explored. Based on our recent
data showing that ETAR/β-arr-1 interaction is critical in cancer progres-
sion, here we examined whether NF-κB is a downstream signal of the
ET-1/ETAR pathway and the involvement of β-arr1. We found that, in
EOC cells expressing high levels of β-arr-1 (Rosanò et al., 2013b), ET-1
treatment promotes a significant NF-κB activation, that can be con-
trolled by ETAR blockadewith the use of a specific antagonist. Moreover,
our results suggest that β-arr1 forms a complex with p65 in the nucleus
following ET-1 stimulation, that might be critical for its ability to poten-
tiate NF-κB transcriptional activity (Fig. 3).
Previous studies have been reported that ET-1 is capable of activating
the NF-κB signalling cascade via ETAR not only in normal cells but also inl ovarian cancer cells. ET-1 binding on ETAR induces β-arr1 recruitment. In the cytosol, ET-1
he activation of theNF-κB pathway. In ET-1-dependentmanner,β-arr-1 links p65 subunits
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2007; Mangelus et al., 2001; Wu et al., 2012; Gerstung et al., 2007).
Our findings indicate that ET-1 activates NF-κB transcriptional activity
in EOC cells, by enhancing phosphorylation of the p65 and IκBα subunit
thus favoring that the free NF-κB might translocate to the nucleus,
where it activates the responsive genes. One of the mechanisms by
which ET-1 might regulate NF-κB activation and transcriptional
response involves the recruitment of β-arr1 and p65 in the nucleus
and scaffolding them together (von Brandenstein et al., 2008). Tran-
scriptional regulation byβ-arr1was reported in other studies, contribut-
ing in the regulation of GPCR-dependent expression of different genes,
including p27 and c-fos, IFN-γ, VEGF, and ET-1 (Rosanò et al., 2013b;
Wang et al., 2006; Kang et al., 2005; Shenoy et al., 2012). Indeed, previ-
ousworks have shown thatβ-arr-1 is actively imported into the nucleus,
and that an intact N domain (amino acids 1–185) is required for this
import (Scott et al., 2002; Wang et al., 2003). A more recent paper
reported the identification of a novel nuclear localization sequence in
β-arr1, mediating active transport of β-arr1 into the nucleus, indepen-
dent of its membrane and cytosolic functions (Hoeppner et al., 2012).
Moreover, previous reports indicated that in the cytosolic compartment,
β-arrs bind to several NF-κB proteins, including p105 and the inhibitory
protein IκBα, capable of functioning as negative or positive regulators of
NF-κB signalling in a different cell type and in a GPCR-dependent man-
ner (Wang et al., 2006; Luan et al., 2005; Witherow et al., 2004; Gao
et al., 2004; Gerstung et al., 2007; Parameswaran et al., 2006). Further-
more, GPCRs associate with β-arrs upon stimulation by their ligands
such as lysophosphatidic acid (LPA) (Kizaki et al., 2009; Gesty-Palmer
et al., 2005) or neurotensin (Law et al., 2012) to activate NF-κB signal-
ling. In particular, β-arr2 is required for LPA-induced NF-κB activation
through recruiting CARMA3 to its receptor, functioning as a positive
regulator for LPA-induced NF-κB activation and cytokine production
(Kizaki et al., 2009). Moreover GPCR-induced nuclear translocation of
β-arr1 increases NF-κB transcriptional responsiveness (Hoeppner
et al., 2012). In linewith these findings, our results support an important
function of β-arr1 in ETAR-driven NF-κB transcriptional regulation in
tumor cells. However, the underlying mechanisms are to be explored.
In particular, how exactly β-arr1 andmembers of theNF-κB complex al-
lows nuclear translocation has yet to be determined. Study from
Hoeppner et al. (2012) indicates that β-arrestin-1 is not involved in
shuttling the members of the NF-κB pathway into and out of the nucle-
us, and that p65 is able to translocate into the nucleus independent of
the translocation of β-arrestin-1, but the accumulation of β-arrestin-1
in the nucleus contributes significantly to NF-κB activation. They also
demonstrated that one of the mechanisms by which β-arrestin-1 mod-
ulates NF-κB transcriptional activity involves the recruitment of CBP/
p300 and a protein kinase to p65 in the nucleus and scaffolding them
together, contributing to the phosphorylation and acetylation of p65
and increased transcriptional responsiveness (Hoeppner et al., 2012).
In this regard, our previous studies demonstrated that, in an ET-1/
ETAR-dependent manner β-arr1, but not β-arr2, is able to shuttle from
the cytoplasm to the nucleus in a time- and dose-dependent manner,
indicating that ET-1 controls the nuclear trafficking ofβ-arr1most likely
tomodulate nuclear signalling of ETAR in EOC cells. Thus, in response to
ETAR activation, β-arr1 increases its nuclear translocation and form a
transcriptional complex, promoting histone acetylation, and gene tran-
scription, required for cell migration, and invasion (Rosanò et al.,
2013b), suggesting that also epigenetic modification-driven by nuclear
function ofβ-arr1might control NF-κB transcriptional activity. Accord-
ing to these findings, other studies demonstrated that β-arr-1
controls the recruitment of specific transcription factors, such as E2F
and HIF-1, or epigenetic modifiers, such as histone acetyltransferase
p300, and gene transcription (Kang et al., 2005; Shenoy et al., 2012;
Hoeppner et al., 2012). Although these findings ascribe the regulation
of gene transcription to β-arr-1 nuclear function, themajority of under-
lying molecular mechanisms and pathophysiological significance re-
main to be elucidated. NF-κB can transcriptionally regulate a diversearray of genes encoding proteins and microRNAs that regulate a wide
range of biological effects. These include cytokines, chemokines and
their respective receptors, which are traditionally associated with the
important role of NF-κB in the inflammatory response, together with
genes regulating cell survival, proliferation, cell adhesion and the cellu-
lar microenviroment (Perkins, 2012). Therefore, understanding how
ETAR induce NF-κB signalling through nuclear β-arr1 function is of in-
terest in uncovering additional pathophysiological functions of β-arr1
during ovarian tumor progression, not only promoting cancer cell surviv-
al, cell proliferation or angiogenesis, but also by regulating the expression
of MMPs associated with the metastatic potential of EOC cells. Recent
studies determined the ability of ET peptides and related agonists to re-
cruit β-arrestin via ETA and ETB receptors and to compare the ability of
well characterized ET-1 receptor selective and non-selective antago-
nists to block these responses (Maguire et al., 2012). Therefore further
understanding of the potential contribution of β-arrestin mediated sig-
nalling to endothelin receptor function as well as the differences in the
pharmacology of ET-1 receptor antagonists in neoplastic diseases is
required.
Conclusions
In conclusion, we identify a novel role of β-arr-1 as a nuclear
platform in mediating ET-1-induced NF-κB responses. Hence, our
study, revealing a previously unrecognized pathway for regulating
cellular responsiveness to ET-1, provides further mechanistic insights
bywhichβ-arr-1 represents the initial scaffold onwhich transcriptional
regulatory complexes could be built to regulate different biological
outcomes. Distinct β-arr1-complexes can recruit with factors that regu-
late the transcription of specific target genes, orchestrating the network
that regulates tumor progression. Our findings indicating that nuclear
β-arr-1-NF-κBnuclear complexes are essential for ETAR signalling trans-
duction provide further insight into the role of β-arr-1 in tumor pro-
gression. Further investigation is needed to address the functional
effects ofβ-arr1-drivenNF-κB signalling in EOC cells, such as cell surviv-
al and invasiveness.
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